Edwards Lifesciences
(NYSE: EW)
reported Street-beating Q2 results, upping the lower end of its full-year sales guidance.
The Irvine, California–based maker of TAVR and other cardiology treatment tech earned $335.9 million, or 57¢ per share, off of $1.53 billion in sales for the quarter that ended June 30, 2025. The bottom line decreased by 7.7%, but the top line increased by 11.9% compared to Q2 2024.
TAVR sales of $1.1 billion were up 8.9% year-over-year. Transcatheter mitral and tricuspid therapies (TMTT) were $134.5 million, up 61.9%. (In May, competitor Boston Scientific discontinued its Accurate TAVR systems amid heightened U.S. and EU regulatory requirements.)
Adjusted to exclude one-time items, Edwards Lifesciences had a Q2 EPS of 67¢, a nickel ahead of the Wall Street consensus of 62¢ and $1.49 billion in revenue.
EW shares were up more than 3% to $78.41 apiece by mid-day trading today, following the company’s earnings announcement after market close yesterday.
Amid the strong Q2 results, Edwards Lifesciences is increasing full-year sales growth guidance to 9–10% from the previous 8–10%, and TAVR sales growth guidance to 6–7% from 5–7%. The company is increasing its adjusted EPS guidance to the high-end of $2.40– 2.50.
“We are pleased to report strong second-quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, we are confident in our full-year outlook and are raising our sales and EPS guidance,” Edwards Lifesciences CEO Bernard Zovighian said in a news release.
“Edwards is increasingly distinguished by our balanced portfolio of leading therapies across aortic, mitral and tricuspid which will position us for leadership for many years to come as we help even more patients around the world.”
Looking forward, company management expects an eventual benefit from an asymptomatic TAVR indication, for which Sapien 3 received FDA approval in May, according to Truist analysts. Boston Scientific’s TAVR exit could also provide a modest contribution to European TAVR sales, though the analysts also saw uncertainty over whether Boston Scientific customers in Europe are willing to sign longer-term contracts with Edwards.
Analysts led by Brandon Vazquez at William Blair see notable TMTT tailwinds for Edwards Lifesciences, including the ramping up of its Pascal transcatheter valve repair system, the FDA-approved Evoque replacement tricuspid valve, and potential first-half 2026 U.S. approval of Sapien M3.
Said Marie Thibault and her colleagues at BTIG: “EW seems to be firmly back on track.”
This story originally ran on July 24, 2025. Updated July 25 with next-day stock price and analyst comments.
